We review the latest literature on the neuropharmacological treatments for acquired nystagmus. Nystagmus may have a significantly impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Competing interests None.
Provenance and peer review commissioned; externally peer reviewed. This paper was reviewed by Mark Lawden, Leicester, UK.
Read the full text or download the PDF:
Other content recommended for you
- Drug treatments for eye movement disorders
- Gaze fixation deficits and their implication in ataxia–telangiectasia
- Diplopia and eye movement disorders
- Pontine lesions mimicking acute peripheral vestibulopathy
- The effects of gabapentin and memantine in acquired and congenital nystagmus: a retrospective study
- 4-aminopyridine restores visual ocular motor function in upbeat nystagmus
- Gabapentin but not vigabatrin is effective in the treatment of acquired nystagmus in multiple sclerosis: how valid is the GABAergic hypothesis?
- Upbeat nystagmus: clinicoanatomical correlation
- Use of HINTS in the acute vestibular syndrome. An Overview